跳至主要内容
临床试验/NCT00302770
NCT00302770终止3 期

Efficacy of Quetiapine in Generalised Social Anxiety Disorder, a Double-blind, Placebo-controlled Study

AstraZeneca1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2006年6月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
终止
发起方
AstraZeneca
入组人数
50
试验地点
1
主要终点
Change on Lebowitz Social Anxiety Scale (LSAS) from baseline to endpoint

研究概览

简要总结

This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with the LSAS

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written Confirmed Consent,
  • All patients meet the DSM IV criteria for generalized social anxiety disorder,
  • A score ≥ 60 on the LSAS,
  • male and female aged between 18 and 65 years

排除标准

  • Presence of any primary axis I diagnosis other than social anxiety disorder according to DSM-IV,
  • alcohol and/or substance abuse according to DSM-IV criteria within the last 12 months,
  • any personality disorder as the primary diagnosis, with the exception of avoidant personality disorder,
  • patients at risk of suicide

结局指标

主要结局

Change on Lebowitz Social Anxiety Scale (LSAS) from baseline to endpoint

次要结局

  • Number of responders, time to onset of response of sustained response to treatment

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验